Heartflow (HTFL) Q1 2026 earnings review
Top-Line Beats and Margin Expansion Eclipsed by Surging OpEx
Heartflow started 2026 with an aggressive top-line beat, raising full-year revenue guidance from $220M (midpoint) to $230M and demonstrating accelerating momentum with 41% YoY Q1 growth. Non-GAAP gross margins surpassed 80% thanks to AI processing efficiencies. However, the profitability narrative is reversing. Non-GAAP operating expenses spiked to 110% of revenue, eroding the operating leverage gained in late 2025. While management's vision of an AI-driven cardiology platform is materializing in sales, the absolute cash burn remains a persistent drag on the bottom line.
🐂 Bull Case
Management significantly raised FY26 revenue expectations to $228M-$232M (30.5% midpoint YoY growth) and bumped non-GAAP gross margin targets to ~81%. The core FFRCT business is proving highly durable.
Non-GAAP gross margins expanded to 80.5% from 75.3% a year ago. The company's 'Autonomous Processing' AI initiative is successfully driving production efficiencies even as case volumes surge.
🐻 Bear Case
Despite a massive 41% jump in revenue, non-GAAP net operating loss actually worsened to $15.5M YoY. Sales and R&D hiring is currently outpacing revenue growth, pushing the profitability horizon further out.
The company absorbed a $7.5M non-cash impairment charge to exit its Mountain View facility and relocate to San Francisco, representing an unforced drag on GAAP profitability.
⚖️ Verdict: ⚪
Neutral. The commercial execution and product adoption are undeniably strong, warranting the guidance raise. However, the aggressive re-acceleration of operating expenses contradicts the margin expansion story, making the path to positive cash flow look increasingly expensive.
Key Themes
Autonomous Processing Drives Margin Acceleration
Heartflow's gross margin trajectory is accelerating. Non-GAAP gross margin reached 80.5% (up from 79.9% in 25Q4 and 75.3% in 25Q1). Management explicitly links this to their AI efficiency initiative, 'Heartflow Autonomous Processing', which automates case processing and directly reduces cost of revenue despite a massive influx in volume.
Plaque Analysis Ramp Pacing Ahead of Schedule
The adoption of Heartflow Plaque Analysis is accelerating faster than management initially projected. Supported by a massive proprietary dataset that recently expanded to over 200 million annotated CCTA images, this product is shifting the company from a single-product FFRCT vendor to a multi-tool diagnostic platform.
US FFRCT Volumes Pushing Top-Line
The core domestic business remains highly stable and robust. US revenue hit $48.3 million, up 42% YoY, primarily driven by underlying FFRCT volume growth. This highlights strong clinical integration across their 1,465+ site installed base.
Operating Expense Ratio is Reversing
A major contradictory data point in this quarter's release: while management touts AI-driven margin expansion, operating discipline deteriorated. Non-GAAP operating expenses jumped to 110% of revenue ($57.8M) in 26Q1, reversing the operating leverage seen in 25Q4 when expenses were down to 105% of revenue. The culprit: aggressive hiring in sales and R&D. True profitability requires this metric to trend downward.
International Adoption Lags US Growth
International revenue remains a laggard. While the US grew 42% YoY, International segments grew only 34%, bringing in a modest $4.3 million. Despite operating in a global market, Heartflow has not yet replicated its domestic commercial engine abroad, capping its near-term Total Addressable Market (TAM) realization.
Macro Tailwind: CCTA Becoming Standard of Care
Heartflow continues to ride the macro shift of Coronary Computed Tomography Angiography (CCTA) replacing traditional stress testing as the frontline diagnostic for coronary artery disease. With the broader CCTA market only 10-12% penetrated, Heartflow's platform—now guiding care for over 650,000 patients—is perfectly positioned to capture organic volume growth.
Headquarters Relocation and Impairment Charge
The company recognized a $7.5 million non-cash impairment charge connected to the right-of-use asset for its Mountain View facility as part of a headquarters relocation to San Francisco. While non-cash, it signals potential operational disruption and real estate mismanagement at a time when cash conservation should be a priority.
Other KPIs
Improved from a $19.2M loss in 25Q1, but actually expanded sequentially compared to the $9.8M loss in 25Q4. The sequential deterioration in the bottom line, despite record revenue, directly reflects the aggressive ramp in SG&A and R&D spending.
Down slightly from $280.2 million at the end of 2025. The balance sheet remains highly stable and adequately capitalized to fund current operating losses without near-term dilution risk, especially following the full retirement of debt in the prior year.
Guidance
Accelerating. Management raised previous guidance of $218-$222 million, now implying 29% to 32% YoY growth. This reflects high confidence in sustained FFRCT momentum and the early-than-expected commercial ramp of the Plaque Analysis product.
Stable to slightly accelerating. The company bumped its target from 80-81% to a firm 81%, reflecting structural gains from the 'Heartflow Autonomous Processing' AI rollout outperforming internal productivity models.
Key Questions
Operating Leverage Timeline
Non-GAAP operating expenses increased to 110% of revenue this quarter, up from 105% in Q4. What specific commercial or R&D investments drove this sudden spike, and when do you expect operating expenses to grow slower than revenue?
Plaque Analysis Specifics
You noted Plaque Analysis is 'ramping ahead of schedule.' Can you break out exactly how much revenue in Q1 came from Plaque versus core FFRCT, and what is the current attachment rate?
International Growth Bottlenecks
International revenue continues to grow slower than the US business (34% vs 42%). What are the primary structural barriers—reimbursement, competitive AI vendors, or sales force maturity—preventing OUS growth from matching domestic velocity?